Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.59 AUD
Change Today 0.00 / 0.00%
Volume 497.5K
BLT On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
NASDAQ CM
As of 11:11 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Katherine A. High M.D.

AgeTotal Calculated CompensationThis person is connected to 18 board members in 2 different organizations across 6 different industries.

See Board Relationships
63$571,304

Background*

Dr. Katherine A. High, also known as Kathy, M.D. has been the President and Chief Scientific Officer at Spark Therapeutics, Inc. since September 16, 2014. Dr. High serves as Scientific Co-Founder and Advisor at Spark Therapeutics, Inc. (a/k/a, Spark Therapeutics, LLC). She began her career the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders studies. Her work has evolved to encompass clinical translation ...

Read Full Background

Corporate Headquarters*

F6A/1-15 Barr Street
Sydney, New South Wales 2041

Australia

Phone: 61 2 9555 6986
Fax: 61 2 9818 2238

Board Members Memberships*

2014-Present
Co-Founder, President, Chief Scientific Officer, Director and Chairman of Scientific & Technology Committee

Education*

BA
Harvard University
MD
University of North Carolina at Chapel Hill School of Medicine
Master's Degree
The University of Pennsylvania

Other Affiliations*

Annual Compensation*

Salary$108,538
Total Annual Compensation$108,538

Stock Options*

Restricted Stock Awards$408,701
All Other Compensation$8,169
Unexercisable Options158,249
Total Number of Options158,249

Total Compensation*

Total Annual Cash Compensation$162,603
Total Short Term Compensation$108,538
Other Long Term Compensation$416,870
Total Calculated Compensation$571,304
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLT:AU A$0.59 AUD 0.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Edward O. Lanphier IIFounder, Chief Executive Officer, President, Director and Member of Clinical Review Committee
Sangamo Biosciences Inc.
$650.0K
Jörn Aldag Chief Executive Officer, Managing Director and Member of Management Board
uniQure N.V.
€484.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BENITEC BIOPHARMA LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.